These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31882513)

  • 1. E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy.
    Gkogkou P; Peponi E; Ntaskagiannis D; Murray S; Demou A; Sainis I; Ioakeim E; Briasoulis E; Tsekeris P
    In Vivo; 2020; 34(1):453-459. PubMed ID: 31882513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in Non-Small Cell Lung Cancers in Iran.
    Nourmohammadi B; Tafsiri E; Rahimi A; Nourmohammadi Z; Daneshvar Kakhaki A; Cho W; Karimipoor M
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1633-1639. PubMed ID: 31244281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy.
    Kurtul N; Eroglu C; Unal D; Tasdemir EA; Orhan O; Zararsiz G; Baran M; Kaplan B; Kontas O
    Asian Pac J Cancer Prev; 2014; 15(20):8911-6. PubMed ID: 25374228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
    J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Krüppel-Like Factor 8 Overexpression Correlates with Poor Prognosis in Non-Small Cell Lung Cancer.
    Li J; Liu Y; Xue J; Xu M; Zhang J; Liu J; Wang W
    Pathol Oncol Res; 2019 Jan; 25(1):115-121. PubMed ID: 28986741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
    Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
    Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.
    Miao Y; Li AL; Wang L; Fan CF; Zhang XP; Xu HT; Yang LH; Liu Y; Wang EH
    Pathol Oncol Res; 2013 Apr; 19(2):281-6. PubMed ID: 23086683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
    Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
    Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
    Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
    Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis].
    Tang XJ; Zhou QH; Zhang SF; Liu LX
    Ai Zheng; 2005 May; 24(5):616-21. PubMed ID: 15890109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.
    Kook EH; Kim YM; Kim HT; Koh JS; Choi YJ; Rho JK; Kim HR; Kim CH; Lee JC
    Oncol Res; 2010; 18(9):445-51. PubMed ID: 20524402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of Twist, Snail and E-cadherin expression in pathological N0 non-small-cell lung cancer: a retrospective cohort study.
    Wang G; Ma W; Li Y; Jiang Y; Ma G; Zhang X; Meng L; Du J
    Eur J Cardiothorac Surg; 2018 Aug; 54(2):237-245. PubMed ID: 29415155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
    Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
    Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of β-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients.
    Ma H; Wang L; Zhang T; Shen H; Du J
    Tumour Biol; 2016 Jan; 37(1):1341-7. PubMed ID: 26293896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients.
    Zhang X; Han S; Zhou H; Cai L; Li J; Liu N; Liu Y; Wang L; Fan C; Li A; Miao Y
    Mol Carcinog; 2019 May; 58(5):767-776. PubMed ID: 30604908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.